Jylamvo, Therakind’s 2 mg/ml oral solution of methotrexate, granted a Europe-wide Marketing Authorisation by the EMA

29th March 2017

On 29th March 2017, the European Commission adopted the recommendation of the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) (announced in January) to grant a marketing authorisation for Therakind’s 2 mg/ml oral solution of methotrexate, Jylamvo. 

This marketing authorisation will allow Jylamvo to be sold throughout the European Economic Area (EEA) which includes the 28 European Union countries and Norway, Iceland and Liechtenstein.

Jylamvo is licensed for use in adults and children over 3 years old for the treatment of rheumatological disorders (adult and juvenile), adult psoriasis and psoriatic arthritis, and for the maintenance treatment of acute lymphoblastic leukaemia (ALL). It is the first oral liquid formulation of methotrexate to be authorised in Europe for the treatment of polyarthritic juvenile idiopathic arthritis (JIA).

 

To see the announcement of the EMA’s positive opinion on Jylamvo, click here

To see Jylanvo's entry in the European Commission's Community Register of medicinal products for human use, please click here